CORAL GABLES, Fla., May 6, 2024 /PRNewswire/ Relmada Therapeutics, Inc. , a late-stage biotechnology company addressing diseases of the central nervous system , today announced that it will.
CORAL GABLES, Fla., March 12, 2024 /PRNewswire/ Relmada Therapeutics, Inc. , a late-stage biotechnology company addressing diseases of the central nervous system , today announced that it will.
Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated
Relmada s Strong Balance Sheet to Support the Company Through All of 2024 s Expected Critical.
/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.
/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.